2,775
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics

, , , , , , , , , & show all
Pages 1216-1229 | Received 22 Jun 2017, Accepted 11 Aug 2017, Published online: 28 Aug 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Liyu Zhang, Meng Wang, Zeen Zhu, Chenxi Ding, Shengquan Chen, Haibin Wu, Ying Yang, Fengyu Che, Qiao Li & Hui Li. (2021) A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy. International Journal of Nanomedicine 16, pages 3217-3240.
Read now
Jiangang Zhao, Meng Wang, Ying Yang, Guoxia Wang, Fengyu Che, Qiao Li & Liyu Zhang. (2021) CD123 thioaptamer protects against sepsis via the blockade between IL-3/CD123 in a cecal ligation and puncture rat model. Nucleosides, Nucleotides & Nucleic Acids 40:1, pages 16-31.
Read now
Haibin Wu, Liyu Zhang, Zeen Zhu, Chenxi Ding, Shengquan Chen, Ruiping Liu, Huafeng Fan, Yang Chen & Hui Li. (2021) Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy. Drug Delivery 28:1, pages 1166-1178.
Read now
Yuan Tan, Yuejin Li & Faqing Tang. (2019) Nucleic Acid Aptamer: A Novel Potential Diagnostic and Therapeutic Tool for Leukemia. OncoTargets and Therapy 12, pages 10597-10613.
Read now
Meng Wang, Haibin Wu, Qiao Li, Ying Yang, Fengyu Che, Guoxia Wang & Liyu Zhang. (2019) Novel Aptamer-Functionalized Nanoparticles Enhances Bone Defect Repair By Improving Stem Cell Recruitment. International Journal of Nanomedicine 14, pages 8707-8724.
Read now

Articles from other publishers (15)

Yongkang Liao, Shijun Xiong, Zaid Ur Rehman, Xiaoli He, Hongling Peng, Jing Liu & Shuming Sun. (2023) The Research Advances of Aptamers in Hematologic Malignancies. Cancers 15:1, pages 300.
Crossref
Meichen Zhang, Yangyang Ge, Shilin Xu, Xiaocui Fang, Jie Meng, Lanlan Yu, Chenxuan Wang, Jian Liu, Tao Wen, Yanlian Yang, Chen Wang & Haiyan Xu. (2022) Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia. Pharmacological Research 185, pages 106503.
Crossref
Tianyuan Ci, Wentao Zhang, Yingyu Qiao, Huangjuan Li, Jing Zang, Hongjun Li, Nianping Feng & Zhen Gu. (2022) Delivery strategies in treatments of leukemia. Chemical Society Reviews 51:6, pages 2121-2144.
Crossref
Liyu Zhang, Meng Wang, Zeen Zhu, Shengquan Chen, Haibin Wu, Ying Yang, Fengyu Che, Qiao Li & Hui Li. (2021) A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics. Molecular Therapy - Nucleic Acids 26, pages 732-748.
Crossref
Yuspian Nur, Shabarni Gaffar, Yeni Wahyuni Hartati & Toto Subroto. (2021) Applications of electrochemical biosensor of aptamers-based (APTASENSOR) for the detection of leukemia biomarker. Sensing and Bio-Sensing Research 32, pages 100416.
Crossref
Ayşe Hilal Eroğlu Küçükdiler, İrfan Yavaşoğlu, Cem Selim, Cansu Atmaca Mutlu, Abdullah Karakuş, Mahmut Bakır Koyuncu, Oktay Bilgir, Orhan Ayyıldız, Eyüp Naci Tiftik & Ali Zahit Bolaman. (2021) Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey. Leukemia Research Reports 16, pages 100280.
Crossref
Valentina Giudice, Francesca Mensitieri, Viviana Izzo, Amelia Filippelli & Carmine Selleri. (2020) Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases. International Journal of Molecular Sciences 21:9, pages 3252.
Crossref
Magdalena Bamburowicz-Klimkowska, Magdalena Poplawska & Ireneusz P. Grudzinski. (2019) Nanocomposites as biomolecules delivery agents in nanomedicine. Journal of Nanobiotechnology 17:1.
Crossref
Ali Jahanban-Esfahlan, Khaled Seidi, Mehdi Jaymand, Thorsten L. Schmidt, Hasan Majdi, Tahereh Javaheri, Rana Jahanban-Esfahlan & Peyman Zare. (2019) Dynamic DNA nanostructures in biomedicine: Beauty, utility and limits. Journal of Controlled Release 315, pages 166-185.
Crossref
Aditi Singh, Nikolai Norevik Myklebust, Sarah Marie Vie Furevik, Ragnhild Haugse & Lars Herfindal. (2019) Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles. Current Medicinal Chemistry 26:28, pages 5278-5292.
Crossref
Asmaa Reda, Salma Hosseiny & Ibrahim M El-Sherbiny. (2019) Next-generation nanotheranostics targeting cancer stem cells. Nanomedicine 14:18, pages 2487-2514.
Crossref
Meng Wang, Haibin Wu, Mingyue Duan, Ying Yang, Guoxia Wang, Fengyu Che, Bailing Liu, Wei He, Qiao Li & Liyu Zhang. (2019) SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells. Life Sciences 232, pages 116663.
Crossref
Ming Wu, Jiaojiao Chen, Hanitrarimalala Veroniaina, Subhankar Mukhopadhyay, Ziheng Wu, Zhenghong Wu & Xiaole Qi. (2019) Pea-like nanocabins enable autonomous cruise and step-by-step drug pushing for deep tumor inhibition. Nanomedicine: Nanotechnology, Biology and Medicine 18, pages 122-134.
Crossref
Amirhossein Bahreyni, Mona Alibolandi, Mohammad Ramezani, Atefeh Sarafan Sadeghi, Khalil Abnous & Seyed Mohammad Taghdisi. (2019) A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo. Colloids and Surfaces B: Biointerfaces 175, pages 231-238.
Crossref
Shuanghui Yang, Huan Li, Ling Xu, Zhenhan Deng, Wei Han, Yanting Liu, Wenqi Jiang & Youli Zu. (2018) Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies. Molecular Therapy - Nucleic Acids 13, pages 164-175.
Crossref